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Abstract
Background: The Middle East is estimated to have the largest increase in prevalence of diabetes
by 2030; yet there is lack of published data on the incidence of Type 2 diabetes in this region. This
study aimed to estimate Type 2 diabetes incidence and its associated risk factors in an Iranian urban
population.
Methods: Among 3307 non-diabetics ≥ 20 years (mean age 42 ± 13 years, 42% males), glucose
tolerance test was performed at baseline in 1999–2001 and at two consecutive phases in 2001–
2005 and 2005–2008. Diabetes and glucose tolerance status were defined according to the ADA
1997 criteria. Logistic regression was used to determine the independent variables associated with
incident diabetes and their odds ratios (OR).
Results:  After median follow-up of 6 years, 237 new cases of diabetes were ascertained
corresponding to an age and sex standardized cumulative incidence of 6.4% (95%CI: 5.6–7.2) and
incidence rate of 10.6 (9.2–12.1) per 1000 person years. Besides classical diabetes risk factors,
female sex and low education level significantly increased risk of diabetes in age adjusted models.
In full model, the independent predictors were age [OR, 95%CI: 1.2 (1.1–1.3)], family history of
diabetes [1.8 (1.3–2.5)], body mass index ≥ 30 kg/m2 [2.3 (1.5–3.6)], abdominal obesity [1.9 (1.4–
2.6)], high triglyceride [1.4 (1.1–1.9)], Isolated impaired fasting glucose (IFG) [7.4 (3.6–15.0)],
Isolated impaired glucose tolerance (IGT) [5.9 (4.2–8.4)] and combined IFG and IGT [42.2 (23.8–
74.9)].
Conclusion: More than 1% of the Iranian urban population older than 20 years develops Type 2
diabetes each year. Combination of IFG and IGT was the strongest predictor of incident diabetes
among the modifiable risk factors.
Background
Type 2 diabetes has reached epidemic levels in most pop-
ulations and epidemiological evidence suggests that
unless effective preventive measures are implemented, the
prevalence continue to raise globally [1] It is estimated
that by the 2030 the number of people with diabetes will
increase to more than 366 million, more than twice the
number in 2000 [2]. Most of these new cases are from
developing countries and it seems that the Middle East is
among the regions that will have the largest increase in
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prevalence of diabetes by 2030 [3]. The occurrence of
rapid and major lifestyle changes in these countries has
increased the prevalence of obesity and other non-com-
municable disease risk factors (like hypertension and dys-
lipidemia) which have been reported to be the major
etiologic factors behind the rising incidence of type 2 dia-
betes around the globe [4]. Identification of these risk fac-
tors is the most important step in development of
preventive strategies in any population because it has
been shown that reduction of such risk factors may reduce
the incidence of Type 2 diabetes [5].
The prevalence of diabetes in the Middle Eastern countries
is known to be high. It is reported to be 29% in United
Arab Emirate [6], and 16.1% in Oman [7]. Recent
national survey in Iran showed the prevalence to be 7.7%
in subjects 25–65 years [8] and it has been reported to be
even higher in the capital city, Tehran (14.0%) [9]. How-
ever no report about the incidence of Type 2 diabetes has
yet been published in these populations. We aimed to
determine the incidence of type 2 diabetes and its associ-
ated risk factors by using standardized oral glucose toler-
ance test (OGTT) in a large population based study in a
representative sample of the population of Tehran called
the Tehran Lipid and Glucose Study (TLGS).
Methods
Study population
The TLGS is a prospective population based study per-
formed on a representative sample of the Tehran popula-
tion, with the aim of determining the prevalence of non-
communicable disease (NCD) risk factors and developing
a healthy lifestyle to improve them [10]. The baseline sur-
vey was performed from 1999 to 2001 and 4751 families
which included more than 15000 residents of district 13
of Tehran aged over 3 years were selected by cluster ran-
dom-sampling method. After this cross-sectional preva-
lence study of NCD risk factors, subjects entered into a
cohort and a prospective interventional study. The cohort
group constituted of 6437 subjects over 20 years. After
exclusion of subjects with prevalent diabetes at baseline
(n = 698) and those with missing data regarding fasting
and 2-hours glucose (n = 625), there were 5114 non-dia-
betic subjects in the cohort group which were reexamined
in 2 consecutive phases, one from 2002 to 2005 (phase 2)
and another from 2005 to 2008 (phase 3) (Figure 1).
Those who developed diabetes in the follow-up examina-
tions (phase 2 or 3) and those who completed the phase
3 examination were included in the current study. The
main reasons for lack of attendance at follow-up examina-
tions despite repeated calls were either migration or other
personal reasons. The proposal of this study was approved
by the research council of The Research Institute for Endo-
crine Sciences of Shahid Beheshti University (M.C) and
informed written consent was obtained from each subject.
Clinical, anthropometric, and laboratory measurements
Subjects were interviewed privately, face-to-face by
trained interviewers using pretested questionnaires. Ini-
tially, information on demographics, education, smoking
status, and medical and drug history was collected.
Anthropometric measures including weight, height, waist
circumference (WC) was measured according to a stand-
ard protocol [10]. Body mass index (BMI) was calculated
as weight in kg divided by height in m2. Systolic and
diastolic blood pressures were measured twice in a seated
position in the right arm and the mean value was consid-
ered as the subject's blood pressure. A blood sample was
taken after 12–14 h overnight fasting and was centrifuged
within 30–45 min of collection. All blood analyses were
performed at the TLGS research laboratory on the day of
blood collection. For OGTT, 82.5 g glucose monohydrate
solution (equivalent to 75 g anhydrous glucose) was
administered orally to subjects and a blood sample was
taken 2 hours later. The analysis of samples was per-
formed using a Selectra 2 auto-analyzer (Vital Scientific,
Spankeren, Netherlands). Fasting and 2-hours plasma
glucose (FPG and 2 hPG respectively) were measured by
enzymatic colorimetric method using glucose oxidase kit
(Pars Azmoon Inc., Tehran, Iran); inter-and intra-assay
coefficient of variations (CV) were less than 2.2%. For
lipid measurements, total cholesterol and triglyceride kits
(Pars Azmoon Inc., Tehran, Iran) were used. Triglycerides
(TGs) were assayed using enzymatic colorimetric assay
with glycerol phosphate oxidase. HDL-cholesterol (HDL-
C) was measured after precipitation of the apolipoprotein
B containing lipoproteins with phosphotungistic acid. All
samples were analyzed when internal quality control met
the acceptable criteria. Inter- and intra-assay coefficients
of variation were 2 and 0.5% for HDL-C and 1.6 and 0.6%
for triglyceride respectively. The glucose measurements
were conducted by the same method at the baseline and
follow-up examinations and inter-and intra-assay CVs for
the follow-up examinations were less than 3.3%.
Definition of variables and outcomes
Education was categorized into 3 groups: illiterate/pri-
mary school, high school and diploma and higher. Posi-
tive family history of diabetes was defined as having at
least one parent or sibling with diabetes. History of cardi-
ovascular disease (CVD) was defined as previous ischemic
heart disease and/or cerebrovascular accidents. We used
1997 American Diabetes Association (ADA) definitions of
diabetes (FPG ≥ 7.0 mmol/l, 2 hPG ≥ 11.1 mmol/l or tak-
ing of anti-diabetic medication), isolated impaired glu-
cose tolerance (IGT, 2 hPG 7.8–11 mmol/l and FPG<6.1
mmol/l), isolated impaired fasting glucose (IFG, FPG 6.1–
6.9 and 2 hPG<7.8 mmol/l) and combined IFG and IGT
(IFG/IGT, FPG 6.1–6.9 and 2 hPG 7.8–11 mmol/l)[11].
Type 2 diabetes risk factors were defined as follows: obes-
ity: BMI<25 (normal weight), 25–29.9 (overweight) and ≥BMC Public Health 2009, 9:186 http://www.biomedcentral.com/1471-2458/9/186
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30 kg/m2 (obese); abdominal obesity: WC>88 or >102 cm
in females and males respectively; hypertension: blood
pressure ≥ 140/90 and/or taking of antihypertensive med-
ication; high TG: Triglyderide>2.2 mmol/l; Low HDL:
HDL-C<1.0 or <1.3 mmol/l in males and females respec-
tively [12].
Statistical Analyses
Baseline characteristics of the participants and non-partic-
ipants in the follow-up examination were compared by
Chi-square, student t and Mann-Whitney test as appropri-
ate. Sampling weights, which accounted for the unequal
probabilities of selection resulting from the complex
design and non-response adjustment factors based on Ira-
nian census bureau data (2006) on age and gender, were
incorporated to all of the estimation processes. Cumula-
tive incidence of diabetes with 95% (CI) was calculated
for each risk factor category by dividing the number of
new cases of Type 2 diabetes (drug treated and newly diag-
nosed) to the total number of subjects in that group. Inci-
dence rate of diabetes was also calculated for the entire
cohort by dividing the total number of incident cases to
the total person-years (PY) of follow-up. Age and sex
standardized incidence was estimated by direct method
using the 2006 population data from the national census
bureau. Cumulative incidences were compared by Chi-
square test. The association of different categorical risk
factors (except age) with incident diabetes was first
assessed by calculating age adjusted odds ratios (ORs)
with 95% CI using logistic regression analysis. The poten-
tial risk factors were age, sex, current or past smoking, edu-
cation level, family history of diabetes, history of CVD,
Follow-up status of the TLGS participants after the baseline examination Figure 1
Follow-up status of the TLGS participants after the baseline examination.BMC Public Health 2009, 9:186 http://www.biomedcentral.com/1471-2458/9/186
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hypertension, BMI 25–29.9 and ≥ 30 kg/m2, abdominal
obesity, IFG, IGT, IFG/IGT and dyslipidemia (high TG and
Low HDL-C). For risk factors with more than 2 categories
the first category was considered as the reference group
and the p-value was calculated for linear trend in the risk.
Those risk factors with a P value less than 0.2 in bivariate
analysis were selected to enter into the multivariate model
and the final model was constructed by backward step-
wise method with P values of 0.1 set as the significance
level for removal from the model. Statistical analysis was
performed by using STATA version 9.0. Two sided P values
less than 0.05 was considered as statistically significant.
Results
The baseline characteristics of the study population are
presented in Table 1. The mean age and BMI of study pop-
ulation were 42 years and 26.7 kg/m2 respectively. Over-
all, 3307 individuals from the 5114 non-diabetics at
baseline either developed diabetes or completed the
phase 3 examination (Figure 1). The median follow-up
duration was six years. Comparison of responders and
non-responders showed that the formers had higher base-
line family history of diabetes, diastolic blood pressure,
BMI, WC and TG. No significant difference was found
between the two groups in baseline age, systolic blood
pressure, FPG, 2 hPG and HDL-C (Table 1).
Overall, 237 new cases of Type 2 diabetes were identified
after a median follow-up of six years which resulted in a
crude cumulative incidence 7.2 (95%CI: 6.3–8.1). The age
and sex standardized cumulative incidence was 6.4 (95%
CI: 5.6–7.2). The crud and adjusted incidence rate were
11.9 (10.5–13.6) and 10.6 (9.2–12.1) per 1000 PY respec-
tively. Table 2 reports the cumulative incidence and ORs
of type 2 diabetes stratified by different risk factors. Risk
of diabetes was 30% higher in females after age adjust-
ment. The incidence increased as the subjects got older
and reached a plateau in 65 years, after which it did not
increase further (cumulative incidence of 12.1 vs. 12.6%
in 50–64 and ≥ 65 years age group respectively, P = 0.7).
The highest increase in incidence was detected in the 35–
49 years group in which it increased nearly 2.5 times com-
pared to the younger group (20–34 years). Most of the
237 incident cases belonged to the 35–49 years group
(37.1%) followed by 50–64 (36.3%), 20–34 (15.6%) and
≥ 65 (11.0%) years. The mean age at diagnosis of diabetes
was 48(12) years. Incidence of diabetes was higher in
those with past history of CVD; however this association
was lost after age adjustment. Current or past smoking did
not increase the incidence of diabetes. Higher education
significantly decreased incidence of diabetes and those
with diploma or higher degrees had 50% lower risk of
developing diabetes than those who were illiterate or had
primary school certificate. As expected, positive family
history of diabetes, BMI 25–29.9 and ≥ 30 kg/m2, abdom-
inal obesity, hypertension, high TG, low HDL-C, IFG, IGT
and IFG/IGT were all significant predictors of incident
diabetes in the age adjusted model with ORs ranging from
1.4 to 42.2. In age adjusted models, the rate of conversion
to Type 2 diabetes in individuals with IFG, IGT and IFG/
IGT was 8.3, 7.1 and 42.2 times higher than that of sub-
jects with normal FPG and 2 hPG respectively.
All the variables with p value of less than 0.2 in the age
adjusted model, namely age, sex, family history of diabe-
tes, education level, BMI 25–29.9 and ≥ 30 kg/m2,
abdominal obesity, hypertension, high TG, low HDL-C,
IFG, IGT and IFG/IGT were selected to enter into the final
model. There was no interaction between sex and any
other selected variables; hence no separate analysis was
performed for men and women. Categories of BMI and
abdominal obesity were fitted separately into the model
to prevent co-linearity. However, since the calculated ORs
and P values for all the other variables in the final model






Age (years) 42 (13) 41 (15) 0.8
Sex (% males) 42.0 43 0.2
Family history of diabetes (%) 27 24 0.006
Systolic blood pressure(mm/Hg) 118 (18) 118 (18) 0.9
Diastolic blood pressure(mm/Hg) 78 (10) 77 (11) 0.02
Waist circumference (cm) 88 (12) 87 (12) 0.01
Body mass index (kg/m2) 26.7 (4.7) 26.3 (5.2) 0.004
Fasting plasma glucose (mmol/l) 5.0 (0.5) 4.9 (0.5) 0.3
2-hours plasma glucose (mmol/l) 5.9 (1.6) 5.9 (1.6) 0.8
Triglyceride (mmol/l) 1.6 (1.2) 1.5 (1.1) 0.01
HDL-cholesterol (mmol/l) 1.0 (0.2) 1.0 (0.2) 0.5
*Respondents were those who developed diabetes during the follow-up or completed the phase 3 examination. Non-respondents did not 
participate in phase 3 examination.
Data are mean (SD) for continuous (median with inter-quartile range for Triglyceride) and % for categorical variables.BMC Public Health 2009, 9:186 http://www.biomedcentral.com/1471-2458/9/186
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Table 2: Incidence rate and risk of Type 2 diabetes stratified by different risk factors.






Males 1386 91 6.6 (5.3–8.0) 1
Females 1921 146 7.6 (6.4–8.8) 1.3 (1.0–1.7)
All 3307 237 7.2 (6.3–8.1)
Age (years) <0.001
20–34 1108 37 3.1 (2.4–4.6) 1
35–49 1210 88 7.3‡ (5.9–8.9) 2.4 (1.6–3.6)
50–64 711 86 12.1†(9.8–14.7) 4.3 (2.9–6.3)
≥ 65 206 26 12.6 (8.4–17.9) 4.5 (2.6–7.5)
Family history of diabetes <0.001
No 2335 129 5.6 (4.6–6.5) 1
Yes 882 99 11.2‡ (9.2–13.5) 2.4 (1.8–3.2)
History of CVD 0.3
No 3119 215 6.9 (6.0–7.8) 1
Yes 113 16 14.2† (8.3–22.0) 1.3 (0.7–2.3)
Smoking 0.7
Never 2650 189 7.1 (6.2–8.23) 1
Current 361 30 7.2 (5.7–11.7) 1.0 (0.7–1.6)
Past 193 18 7.3 (5.6–14.3) 0.7 (0.4–1.2)
Education 0.001
Illiterate/primary school 972 119 12.2 (10.2–14.5) 1
Secondary school 593 41 6.9‡ (5.0–9.3) 0.8 (0.5–1.2)
Diploma and higher 1740 77 4.4† (3.5–5.5) 0.5 (0.4–0.8)
Hypertension <0.001
No 2657 147 5.5 (4.7–6.5) 1
Yes 631 88 14.0‡ (11.3–16.9) 1.9 (1.4–2.6)
Obesity <0.001
Normal weight 1190 41 3.5 (2.5–4.6) 1
Overweight 1346 86 6.4‡ (5.1–7.8) 1.7 (1.1–2.5)
Obese 771 110 14.3‡ (11.9–16.9) 4.0 (2.7–5.8)
Abdominal obesity 0.001
No 2225 98 4.4 (3.6–5.3) 1
Yes 1038 135 13.0‡ (11.0–15.2) 1.4 (1.3–1.5)
High Triglyceride <0.001
No 2449 136 5.6 (4.7–6.5) 1
Yes 858 101 11.8‡ (9.7–14.1) 2.0 (1.5–2.6)
Low HDL-cholesterol 0.04
No 1001 61 6.1 (4.7–7.8) 1
Yes 2306 176 7.6‡ (6.6–8.8) 1.4 (1.0–1.9)
Glucose tolerance category
Normal 3216 94 2.9 (2.4–3.6) 1 <0.001
Isolated IFG 60 12 20.0 (10.8–32.3) ‡ 8.3 (4.2–16.5)
Isolated IGT 442 85 19.2 (15.7–23.2) 7.1 (5.1–9.8)
IFG/IGT 77 46 59.7 (47.9–70.8) ‡ 42.2 (25.8–75.7)
*Cumulative incidences were compared by Chi-squared test. Odds ratios were calculated by logistic regression analysis after controlling for age. 
For categorical variables with more than 2 values, the first category was considered as the reference and the p-value is for linear trend in risk.
Obesity: BMI<25 (normal), 25–29.9 (overweight) and ≥ 30 kg/m2 (obese), Abdominal obesity: waist circumference>88 or >102 cm in females and 
males respectively, Hypertension: Blood pressure ≥ 140/90 and/or taking of antihypertensive medication, High TG:Triglyderide>2.2 mmol/l, Low 
HDL: HDL-cholesterol <1.0 or <1.3 mmol/l in males and females respectively, Isolated IFG: FPG 6.1–6.9 and 2 hPG<7.8 mmol/l, Isolated 
IGT:FPG<6.1 and 2-hours plasma glucose 7.8–11 mmol/l, IFG/IGT: FPG 6.1–6.9 and 2 hPG 7.8–11 mmol/l.
† and ‡ represent P < 0.05 and P < 0.001 in comparison to the preceding category.BMC Public Health 2009, 9:186 http://www.biomedcentral.com/1471-2458/9/186
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were quite identical whether BMI or abdominal obesity
was in the model and because abdominal obesity fitted
models had higher overall fitness in Hosmer-Lemeshow
test (Chi-square value of 4.1 vs. 9.6), only calculated ORs
of the model that included abdominal obesity were pre-
sented for those variables. For age, OR was calculated per
10 years increase in its value. Table 3 demonstrates the
result of the final logistic regression model with backward
stepwise approach. The highest OR among independent
variables was with IFG/IGT (42.2), followed by IFG (7.4),
IGT (5.9), BMI ≥ 30 kg/m2 (2.3), abdominal obesity (1.9),
family history of diabetes (1.8), hypertriglyceridemia
(1.4), and age (1.2).
Discussion
In this first report of the population based incidence of
diabetes in the Eastern Mediterranean region, which used
FPG and 2 hPG to ascertain glucose tolerance status both
at baseline and at follow-up, we estimated the standard-
ized incidence rate of Type 2 diabetes in a representative
sample of Tehranian adults over 20 years to be 10.6/1000
PY which corresponded to an annual incidence rate of
more than one percent. We also showed that among mod-
ifiable risk factors namely obesity, hypertriglyceridemia
and abnormal glucose tolerance; IFG/IGT was the most
prominent determinant of progression to incident diabe-
tes in the Iranian population.
The incidence rate of Type 2 diabetes in most of the Euro-
pean studies that used similar criteria for classification of
glucose tolerance ranges from 7.6 to 10.8/1000 PY [13-
15]. In particular, in the Ely study in UK the crude inci-
dence rate was 7.5 [14], similar to a recent report in the
Australia (7.0/1000 PY) [16] which are lower than our
results. All of these European populations were older than
ours and none had lower mean BMI. High incidence rate
of diabetes has been reported in Netherland in an old
population with mean age of 60 years [17]. The reported
incidence in the current study is lower than similar popu-
lation based studies in the US with incidence rate of 11.4–
12.8/1000 PY [18-20]. One possible explanation for this
observation is that our population is relatively young
(mean age of 42 years) compared to these studies. The
total and urban population of IRAN in 2006 was more
than 70 and 48.2 million respectively, 64% of which were
over 20 years old. If we extrapolate the standardized
annual rate of the incident diabetes in the present study to
the current urban population of IRAN older than 20 years,
it is estimated that each year more than 310 thousands
individuals develop Type 2 diabetes. This alarming rate
confirms previous estimates that the Middle East region
will have the highest increase in number of diabetes cases
in the following 20 years [21]. This could be due to
changes in life style including dietary habits and physical
activity pattern that has occurred quite rapidly in recent
years due to rapid urbanization and technological transi-
tion and has led to a rapid rise in risk factors of chronic
disease [22]. High incidence rate of type 2 diabetes in our
relatively young population might also be due to ethnicity
which is a known risk factor for diabetes [4].
Identification of those who may be at higher risk of devel-
oping diabetes is usually the first step for the prevention
of Type 2 diabetes. In the present study, age was a signifi-
cant predictor of the incidence in multivariate analysis.
We also found that the highest proportion (37.1%) of
incident cases belonged to the 35–49 years age group. This
is in accordance with a recent consensus statement from
the International Diabetes Federation which states that
the age of onset of diabetes has moved down into younger
adults [1]. Similar to the results of a recent Australian
study [16], we found family history of diabetes to be an
independent predictor of Type 2 diabetes in the full
model. This finding may point to the strong association of
Type 2 diabetes with genetic predisposition in the Iranian
population. Similar to previous reports [16], some of the
major components of the metabolic syndrome including
abdominal obesity and hypertriglyceridemia independ-
ently predicted diabetes development in our population.
This is important especially if one considers the increasing
trend in prevalence of obesity in the TLGS population [23]
and highlights the importance of preventing programs
that target obesity control.
Like many other studies [13,15,16,19,24], we demon-
strated that the strongest predictors of incident diabetes
were abnormal glucose metabolism including IGT, IFG
Table 3: Independent variables associated with incident Type 2 
diabetes and their corresponding odds ratios in the TLGS cohort 
population after median follow-up time of 6 years.
Variables Odds ratio (95%CI) P
Age (per 10 years) 1.2 (1.1–1.3) 0.008
Family history of diabetes 1.8 (1.3–2.5) <0.00
BMI ≥ 30 kg/m2 2.3 (1.5–3.6) <0.001
Abdominal obesity 1.9 (1.4–2.6) 0.001
High triglyceride 1.4 (1.1–1.9) 0.04
Glucose tolerance category
Normal 1 -
Isolated IFG 7.4 (3.6–15.0) <0.001
Isolated IGT 5.9 (4.2–8.4) <0.001
IFG/IGT 42.2 (23.8–74.9) <0.001
Odds ratios were obtained by multivariate logistic regression analysis 
with backward selection. The variables that entered into the model at 
first step were age, sex, education level (Illiterate/primary, secondary, 
diploma/higher), family history of diabetes, hypertension (blood 
pressure ≥ 140/90 mm/Hg and/or taking of antihypertensive 
medication), obesity (BMI<25, 25–29.9 and ≥ 30 kg/m2 with <25 as 
reference group), Abdominal obesity (waist circumference>88 or 
>102 cm in females and males respectively), glucose tolerance 
categories, high triglyceride (>2.2 mmol/l) and low HDL cholesterol 
(<1.0 or <1.3 mmol/l in males and females respectively). BMI 
categories and abdominal obesity were fitted separately into the 
models.BMC Public Health 2009, 9:186 http://www.biomedcentral.com/1471-2458/9/186
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and in particular IFG/IGT. However, the risk associated
with IFG was higher than that with IGT. This is in con-
cordance with most European studies [13,15,17], but in
contrast with the results of studies in Mauritians [25] and
Asians [24] which showed higher risk in subjects with
IGT. This could be due to the difference in the distribution
of IFG and IGT by age and ethnicity as have been previ-
ously stated [26]. In the present study IFG/IGT had the
highest associated risk with incident diabetes among
other risk factors. This is most likely due to the fact that
IFG and IGT have different pathophysiology and confirms
previous report that combining 2 hPG and FPG signifi-
cantly increases the power to discriminate those who
develop diabetes from those who do not[26,27].
The current study has some limitations. First, we lost 30%
of the original cohort in the follow-up examination. In
addition, the comparison of risk profile at baseline
between respondents and non-respondents showed
higher values for some major diabetes risk factors in the
former group which may cause overestimation. However,
these differences, although statistically significant, did not
seem to be clinically important. In addition, the mean val-
ues of FPG and 2 hPG as well as prevalence of IFG, IGT
and IFG/IGT (data not shown), which were the strongest
predictors of Type 2 diabetes, were not different in
respondents and non-respondents. Second, we did not
measure the association of physical activity with incident
diabetes because our instruments used for assessing phys-
ical activity suffered from lack of accuracy as do any ques-
tionnaire used in epidemiological studies [28]. Third,
there are uncertainties about generalizability of our results
to ethnic groups other than those in the study and to other
geographic regions of the country. The major strengths of
the present study is being population based with large
number of participants, using FPG and 2 hPG for detect-
ing undiagnosed diabetes both at baseline and at follow-
up, as well as adjusting for the major diabetes risk factors
and confounders.
Conclusion
In conclusion, Type 2 diabetes is increasing at a rate of
nearly 1% per year in the Iranian urban population espe-
cially in those who are aged, obese or have abnormal glu-
cose tolerance. Special attention in terms of preventive
strategies must be paid to individuals with abnormal glu-
cose tolerance, as this state was the most prominent pre-
dictor of developing type 2 diabetes.
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